News
Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt ...
The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...
A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...
Formycon currently anticipates that FYB206 could enter the U.S. market after Keytruda’s exclusivity expires in 2029, and in ...
StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...
The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...
Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...
Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches.
Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...
Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results